Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8772228,half-life,BM 06.022 was injected at a pharmacological dose of 380 micrograms/kg b.w. and it was cleared from the plasma in a biphasic manner with a half-life of about 1 min in the alpha-phase and t1/2 of 20-28 min in the beta-phase.,"Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772228/),min,1,10849,DB00015,Reteplase
,8772228,t1/2,BM 06.022 was injected at a pharmacological dose of 380 micrograms/kg b.w. and it was cleared from the plasma in a biphasic manner with a half-life of about 1 min in the alpha-phase and t1/2 of 20-28 min in the beta-phase.,"Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772228/),min,20-28,10850,DB00015,Reteplase
,8772228,IC50,"BM 06.022 bound with low-affinity to the parenchymal liver cells (550 nM) and the binding of BM 06.022 could be displaced by t-PA (IC50 5.6 nM), indicating that the low-density lipoprotein receptor-related protein (LRP) could be involved in the binding of BM 06.22.","Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772228/),nM,5.6,10851,DB00015,Reteplase
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],4.9,30181,DB00015,Reteplase
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],5.7,30182,DB00015,Reteplase
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],32.1,30183,DB00015,Reteplase
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],82.3,30184,DB00015,Reteplase
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],3.1,30185,DB00015,Reteplase
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],6.3,30186,DB00015,Reteplase
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],33.2,30187,DB00015,Reteplase
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],37.2,30188,DB00015,Reteplase
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,71.9,30189,DB00015,Reteplase
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,130,30190,DB00015,Reteplase
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,62.9,30191,DB00015,Reteplase
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,129.9,30192,DB00015,Reteplase
,1909815,systemic clearance,"The systemic clearance ranged from 2.5 to 3.0 ml.min-1.kg-1 and did not show dose-dependency, in contrast to alteplase which was studied at doses of 200, 400, 800, and 1600 kU/kg.",Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909815/),[ml] / [kg·min],2.5 to 3.0,66036,DB00015,Reteplase
,1909815,dominant half-life,"The dose-groups of BM 06.022 showed an average dominant half-life ranging from 11.6 to 15.4 min, which was about five-times longer than the dominant half-life values of alteplase (2.3 to 4.5 min).",Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909815/),min,11.6 to 15.4,66037,DB00015,Reteplase
,1909815,dominant half-life,"The dose-groups of BM 06.022 showed an average dominant half-life ranging from 11.6 to 15.4 min, which was about five-times longer than the dominant half-life values of alteplase (2.3 to 4.5 min).",Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909815/),min,2.3 to 4.5,66038,DB00015,Reteplase
,1908140,effective dose of 50% thrombolysis (ED50),The effective dose of 50% thrombolysis (ED50) obtained by half-logarithmic regression analysis was 163 kU/kg (= 0.28 mg/kg) for BM 06.022 and 871 kU/kg (= 1.09 mg/kg) for alteplase.,Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),[ku] / [kg],163,79342,DB00015,Reteplase
,1908140,effective dose of 50% thrombolysis (ED50),The effective dose of 50% thrombolysis (ED50) obtained by half-logarithmic regression analysis was 163 kU/kg (= 0.28 mg/kg) for BM 06.022 and 871 kU/kg (= 1.09 mg/kg) for alteplase.,Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),[ku] / [kg],871,79343,DB00015,Reteplase
,1908140,half-life,"Pharmacokinetic analysis for plasma activity at a dose of 400 kU/kg revealed a half-life of 18.9 +/- 1.5 min for BM 06.022, whereas alteplase was distributed with a half-life of 2.1 +/- 0.1 min, accounting for 86.7 +/- 1.9% of the total AUC, followed by a beta-phase with a half-life of 13.8 +/- 0.9 min.",Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),min,18.9,79344,DB00015,Reteplase
,1908140,half-life,"Pharmacokinetic analysis for plasma activity at a dose of 400 kU/kg revealed a half-life of 18.9 +/- 1.5 min for BM 06.022, whereas alteplase was distributed with a half-life of 2.1 +/- 0.1 min, accounting for 86.7 +/- 1.9% of the total AUC, followed by a beta-phase with a half-life of 13.8 +/- 0.9 min.",Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),min,2.1,79345,DB00015,Reteplase
,1908140,half-life,"Pharmacokinetic analysis for plasma activity at a dose of 400 kU/kg revealed a half-life of 18.9 +/- 1.5 min for BM 06.022, whereas alteplase was distributed with a half-life of 2.1 +/- 0.1 min, accounting for 86.7 +/- 1.9% of the total AUC, followed by a beta-phase with a half-life of 13.8 +/- 0.9 min.",Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),min,13.8,79346,DB00015,Reteplase
,1908140,Plasma clearance,Plasma clearance of BM 06.022 was 4.7 +/- 0.7 ml min-1 kg-1 compared with 20 +/- 1.2 ml min-1 kg-1 for alteplase.,Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),[ml] / [kg·min],4.7,79347,DB00015,Reteplase
,1908140,Plasma clearance,Plasma clearance of BM 06.022 was 4.7 +/- 0.7 ml min-1 kg-1 compared with 20 +/- 1.2 ml min-1 kg-1 for alteplase.,Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),[ml] / [kg·min],20,79348,DB00015,Reteplase
,7740462,half-life,Activity assays on serial samples showed a dose-dependent decline of BM 06.022 activity with a half-life from 72 min at 0.3 microgram/ml to 38 min at 10 micrograms/ml.,"In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740462/),min,72,108548,DB00015,Reteplase
,7740462,half-life,Activity assays on serial samples showed a dose-dependent decline of BM 06.022 activity with a half-life from 72 min at 0.3 microgram/ml to 38 min at 10 micrograms/ml.,"In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740462/),min,38,108549,DB00015,Reteplase
,8820418,clearance,"In comparison with sham surgery, 1-hr clamping plus recovery for 6 days had the least effect on inulin clearance, followed by clamping and recovery for 3 days and bilateral nephrectomy (20.2 +/- 1.8 vs. 13.0 +/- 1.3, 8.3 +/- 0.8, and 3.1 +/- 0.2 ml center dot min-1 center dot kg-1, p < 0.01).",Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820418/),[center·center·dot·dot·ml] / [kg·min],20.2,160239,DB00015,Reteplase
,8820418,clearance,"In comparison with sham surgery, 1-hr clamping plus recovery for 6 days had the least effect on inulin clearance, followed by clamping and recovery for 3 days and bilateral nephrectomy (20.2 +/- 1.8 vs. 13.0 +/- 1.3, 8.3 +/- 0.8, and 3.1 +/- 0.2 ml center dot min-1 center dot kg-1, p < 0.01).",Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820418/),[center·center·dot·dot·ml] / [kg·min],13.0,160240,DB00015,Reteplase
,8820418,clearance,"In comparison with sham surgery, 1-hr clamping plus recovery for 6 days had the least effect on inulin clearance, followed by clamping and recovery for 3 days and bilateral nephrectomy (20.2 +/- 1.8 vs. 13.0 +/- 1.3, 8.3 +/- 0.8, and 3.1 +/- 0.2 ml center dot min-1 center dot kg-1, p < 0.01).",Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820418/),[center·center·dot·dot·ml] / [kg·min],8.3,160241,DB00015,Reteplase
,8820418,clearance,"In comparison with sham surgery, 1-hr clamping plus recovery for 6 days had the least effect on inulin clearance, followed by clamping and recovery for 3 days and bilateral nephrectomy (20.2 +/- 1.8 vs. 13.0 +/- 1.3, 8.3 +/- 0.8, and 3.1 +/- 0.2 ml center dot min-1 center dot kg-1, p < 0.01).",Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820418/),[center·center·dot·dot·ml] / [kg·min],3.1,160242,DB00015,Reteplase
,8820418,Total plasma clearance,"Total plasma clearance of reteplase was significantly reduced, compared with sham surgery after 1-hr clamping plus 3-day recovery and bilateral nephrectomy (3.65 +/- 0.26 vs.",Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820418/),,3.65,160243,DB00015,Reteplase
,1914379,D-dimers,Fibrin D-dimers were highest with 1147 +/- 380 ng/ml at 5.5 MU of BM 06.022.,Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914379/),[ng] / [ml],1147,163242,DB00015,Reteplase
,1914379,AUC,"At 5.5 MU of BM 06.022, the AUC was 313 +/- 47 IU.hr.ml-1, the total plasma clearance was 306 +/- 40 ml/min, and the half-life was 14.4 +/- 1.1 minutes.",Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914379/),[h·iu] / [ml],313,163243,DB00015,Reteplase
,1914379,total plasma clearance,"At 5.5 MU of BM 06.022, the AUC was 313 +/- 47 IU.hr.ml-1, the total plasma clearance was 306 +/- 40 ml/min, and the half-life was 14.4 +/- 1.1 minutes.",Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914379/),[ml] / [min],306,163244,DB00015,Reteplase
,1914379,half-life,"At 5.5 MU of BM 06.022, the AUC was 313 +/- 47 IU.hr.ml-1, the total plasma clearance was 306 +/- 40 ml/min, and the half-life was 14.4 +/- 1.1 minutes.",Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914379/),min,14.4,163245,DB00015,Reteplase
,1725068,Half-life,"Half-life of BM 06.022-activity was 11.2 +/- 0.4 min and of antigen was 13.9 +/- 0.7 min, followed by a terminal half-life only for antigen of 173 +/- 33 min.",Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725068/),min,11.2,223487,DB00015,Reteplase
,1725068,Half-life,"Half-life of BM 06.022-activity was 11.2 +/- 0.4 min and of antigen was 13.9 +/- 0.7 min, followed by a terminal half-life only for antigen of 173 +/- 33 min.",Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725068/),min,13.9,223488,DB00015,Reteplase
,1725068,terminal half-life,"Half-life of BM 06.022-activity was 11.2 +/- 0.4 min and of antigen was 13.9 +/- 0.7 min, followed by a terminal half-life only for antigen of 173 +/- 33 min.",Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725068/),min,173,223489,DB00015,Reteplase
,1725068,Plasma clearance,Plasma clearance of BM 06.022 was 371 +/- 13 ml/min for activity and 183 +/- 15 ml/min for antigen.,Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725068/),[ml] / [min],371,223490,DB00015,Reteplase
,1725068,Plasma clearance,Plasma clearance of BM 06.022 was 371 +/- 13 ml/min for activity and 183 +/- 15 ml/min for antigen.,Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725068/),[ml] / [min],183,223491,DB00015,Reteplase
,1719279,re,Comparison with infusion experiments showed that intravenous bolus injection of 140 kU/kg of BM 06.022 was equieffective to a 90-min infusion of 800 kU/kg (= 1 mg/kg) of alteplase as a standard treatment regarding reperfusion rate (66%) and time to reperfusion (15 +/- 6 vs. 18 +/- 8 min).,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),,66,258779,DB00015,Reteplase
,1719279,time to reperfusion,Comparison with infusion experiments showed that intravenous bolus injection of 140 kU/kg of BM 06.022 was equieffective to a 90-min infusion of 800 kU/kg (= 1 mg/kg) of alteplase as a standard treatment regarding reperfusion rate (66%) and time to reperfusion (15 +/- 6 vs. 18 +/- 8 min).,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),min,15,258780,DB00015,Reteplase
,1719279,time to reperfusion,Comparison with infusion experiments showed that intravenous bolus injection of 140 kU/kg of BM 06.022 was equieffective to a 90-min infusion of 800 kU/kg (= 1 mg/kg) of alteplase as a standard treatment regarding reperfusion rate (66%) and time to reperfusion (15 +/- 6 vs. 18 +/- 8 min).,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),min,18,258781,DB00015,Reteplase
,1719279,total plasma clearance,Pharmacokinetic analysis for functionally active BM 06.022 or alteplase in plasma revealed a total plasma clearance of 4.1-6.6 ml/min/kg for BM 06.022 and of 12.6-42.3 ml/min/kg for alteplase.,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),[ml] / [kg·min],4.1-6.6,258782,DB00015,Reteplase
,1719279,total plasma clearance,Pharmacokinetic analysis for functionally active BM 06.022 or alteplase in plasma revealed a total plasma clearance of 4.1-6.6 ml/min/kg for BM 06.022 and of 12.6-42.3 ml/min/kg for alteplase.,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),[ml] / [kg·min],12.6-42.3,258783,DB00015,Reteplase
